PMID- 36706368
OWN - NLM
STAT- MEDLINE
DCOM- 20230215
LR  - 20230215
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 16
IP  - 2
DP  - 2023 Feb
TI  - Real-world clinical effectiveness of once-weekly semaglutide in patients with 
      type 2 diabetes: a systematic literature review.
PG  - 161-176
LID - 10.1080/17512433.2023.2174099 [doi]
AB  - INTRODUCTION: The efficacy of once-weekly (O.W.) semaglutide for the treatment of 
      type 2 diabetes mellitus (T2DM) has been demonstrated in clinical trials. The aim 
      of this systematic literature review was to summarize real-world evidence for 
      O.W. semaglutide. METHODS: A comprehensive search of PubMed, Web of Science, 
      Embase, and Scilit databases was performed from January 2017 to June 2022 to 
      identify eligible real-world studies examining O.W. semaglutide in T2DM. RESULTS: 
      Thirty-one records (18 full-text and 13 abstracts) were identified. The general 
      characteristics of studies and included patients were summarized. Changes in 
      glycated hemoglobin (HbA1c) and body weight were analyzed across studies and 
      according to patient characteristics: baseline HbA1c/weight level, 
      GLP-1 RA-naive/ GLP-1RA-experienced. The effectiveness of O.W. semaglutide 
      compared with dulaglutide, and the dose of O.W. semaglutide in the real world 
      were also summarized. CONCLUSIONS: This systematic literature review provided 
      complementary evidence to findings from the clinical trials and provided a more 
      comprehensive picture of the use of O.W. semaglutide in routine clinical 
      practice. Results of the review suggested that O.W. semaglutide therapy was 
      associated with improving glycemic control and weight loss in both T2DM patients 
      naive to GLP-1RA and those previously treated with other GLP-1RA in routine 
      clinical practice. PROSPERO REGISTRATION: CRD42022306164.
FAU - Ruan, Zhen
AU  - Ruan Z
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macao SAR, China.
FAU - Jiang, Yixuan
AU  - Jiang Y
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macao SAR, China.
FAU - Shi, Honghao
AU  - Shi H
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macao SAR, China.
FAU - Jia, Ruxu
AU  - Jia R
AD  - Global Business School for Health, University College London, London, UK.
FAU - Ung, Carolina Oi Lam
AU  - Ung COL
AUID- ORCID: 0000-0003-1915-5099
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macao SAR, China.
AD  - Department of Public Health and Medicinal Administration, Faculty of Health 
      Sciences, University of Macau, Macao SAR, China.
FAU - Hu, Hao
AU  - Hu H
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macao SAR, China.
AD  - Department of Public Health and Medicinal Administration, Faculty of Health 
      Sciences, University of Macau, Macao SAR, China.
LA  - eng
PT  - Systematic Review
DEP - 20230202
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 53AXN4NNHX (semaglutide)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Glycated Hemoglobin)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Hypoglycemic Agents
MH  - Glycated Hemoglobin
MH  - Drug Administration Schedule
MH  - Glucagon-Like Peptides
MH  - Body Weight
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Effectiveness
OT  - GLP-1RA
OT  - HbA1c
OT  - O.W. semaglutide
OT  - Real-world evidence
OT  - review
OT  - type 2 diabetes
OT  - weight
EDAT- 2023/01/28 06:00
MHDA- 2023/02/16 06:00
CRDT- 2023/01/27 16:23
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/02/16 06:00 [medline]
PHST- 2023/01/27 16:23 [entrez]
AID - 10.1080/17512433.2023.2174099 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2023 Feb;16(2):161-176. doi: 
      10.1080/17512433.2023.2174099. Epub 2023 Feb 2.